Literature DB >> 15291979

New molecular targets for treatment of lymphoma.

Barbara Pro1, Anas Younes.   

Abstract

In recent years, several molecular mechanisms involved in promoting cancer cell survival and growth have been identified. These discoveries helped in designing and testing novel drugs that target specific cellular pathways. In this review, we focus on new molecular targets that are being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15291979     DOI： 10.1007/s11912-004-0062-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  53 in total

Review 1.  CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.

Authors:  P Fiumara; A Younes
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

Review 2.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

3.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

Review 4.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

Review 5.  To die or not to die--the quest of the TRAIL receptors.

Authors:  M Degli-Esposti
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

6.  Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

Authors:  P Fiumara; V Snell; Y Li; A Mukhopadhyay; M Younes; A M Gillenwater; F Cabanillas; B B Aggarwal; A Younes
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

7.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Authors:  Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

8.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines.

Authors:  J C Reed; S Kitada; S Takayama; T Miyashita
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

Review 9.  Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Authors:  Amit Panwalkar; Srdan Verstovsek; Francis J Giles
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

Review 10.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.